Start a Renewal Value Review by Defining the Evidence

A renewal review in biotechnology usually breaks down over one word, value. Procurement wants proof the spending was worth it, research leadership assumes the proof already exists somewhere, and you get pushed toward a number nobody actually tracked during the term. The fix is not a sharper pitch. It is a shared definition of evidence, agreed before anyone claims the agreement paid for itself.

Why This Conversation Goes Wrong

Biotech accounts rarely document the outcomes a renewal is supposed to prove. A lab adopts a platform to speed up a screening process or reduce failed runs, but nobody assigns a metric to that goal at signing, and nobody checks it during the term. Two years later, procurement asks for return on investment as if it were sitting in a report somewhere. It is not. What exists is usage data, support tickets, and a handful of opinions from scientists who liked or disliked the tool.

You feel pressure to fill that gap with a confident claim. Saying the renewal paid for itself, without a number you can defend, is the fastest way to lose credibility in the room. Procurement will ask how you calculated it. If you cannot answer cleanly, the whole conversation shifts from evaluating value to defending your math, and you lose control of the discussion you actually needed to have.

The better move is to name the gap directly. Nobody agreed on success measures at the start, so nobody can produce them now. That is not your failure to fix on the spot. It is the first item on the agenda.

What To Gather Before You Sit Down

Before the meeting, pull three separate categories of information, and keep them separate. Usage records show what actually happened, seat counts, sample volumes processed, feature adoption, response times on support tickets. Support history shows what went wrong and how it got resolved. Then there is everything else, comments from a lab director about efficiency, a hallway remark that the tool saved time, general impressions that were never measured. Label that third category as opinion, not evidence, and do not let it slide into the same column as the usage data.

Figure out who actually needs to be in the room. A procurement director controls the commercial terms, but the person who can validate whether the tool changed lab outcomes probably sits in research operations, not procurement. If you have not mapped who holds which piece of the decision, do that before the meeting instead of during it. The approach described in Map Collaborator Decision Roles in a Shared Research Evaluation applies directly here, since a renewal review has the same problem as any other collaborative evaluation, several people each hold one piece of the answer and none of them can decide alone.

Also decide what you are not going to discuss yet. Pricing and contract terms stay with the people authorized to negotiate them. Bringing commercial numbers into a meeting meant to establish facts turns the conversation into a negotiation before anyone agrees on what is true.

What To Say In The Room

The procurement director opens with a direct challenge. "Can you show me that this renewal actually paid for itself?"

You do not have a defensible number, and pretending otherwise would only delay the real problem. "I do not have a figure I would stand behind, and I would not want you to accept one from me without knowing how it was built. Here is what I can verify. I have usage records and support history for every lab that used this agreement over the past year. What I do not have is a documented set of success measures from when the deal was signed. That is a gap, and I think we should close it together instead of guessing at a number to fill it."

The director pushes back, because her leadership expects an answer. "That is fine, but my team needs something concrete before we sign again."

You redirect toward the actual decision instead of a manufactured figure. "Understood. Before we talk numbers, I want to know what measures matter to your team right now, not just what was written down two years ago. Can you bring in whoever manages lab operations, so the three of us agree on what evidence would actually satisfy both sides?"

That last question usually works, because it hands procurement something more useful than a defended claim, a process they can trust. In the fictional version of this exchange, the director agrees and loops in a lab operations lead for the next session, which is exactly the outcome you want. The conversation moves from an unanswerable question to a plan.

Mistakes That Undermine The Review

A few habits sink this conversation before it starts. First, claiming outcomes you cannot source, saying the agreement improved throughput or cut costs without a number tied to it. Second, mixing usage data with opinion in the same document, so a lab director's offhand comment starts reading like a measured result. Third, letting commercial terms enter the discussion before the group agrees on the facts, which turns a fact finding session into a negotiation nobody was ready for. Fourth, assuming the framework that worked for one account transfers cleanly to another. Accounts differ in what they tracked, who was involved, and what decisions are actually pending, the same reason teams get burned when they copy a pilot setup into a new site without checking whether the assumptions still hold, a pattern covered in Assess a New Research Center Before Copying a Pilot Setup. A review framework has to be built from what this account actually recorded, not from what worked last time.

How To Practice And Score This Skill

The skill here is separating evidence from claims under pressure, and that is hard to learn by reading about it. Give a trainee a mixed folder, usage logs, support notes, and a few opinion statements from a fictional lab team, and ask them to sort the material and write a one paragraph meeting objective. Score the result on three things. Did they keep verified activity separate from unproven claims. Did they name the missing success measures as a gap instead of papering over it. Did they identify who else needs to be in the room before making commitments on behalf of people who were not consulted.

DealSpeak runs this kind of scenario as a rehearsal, where the AI counterpart plays the skeptical procurement director and pushes back the way a real one would. You can find this scenario alongside other Biotechnology practice conversations, built around the situations account managers in this industry actually run into.

The strongest renewal reviews never rest on a single claimed number. They rest on a framework both sides trust, built from evidence that already exists and questions that still need answers. Get that framework right, and the pricing conversation that follows becomes far easier to have.

You can rehearse this exact conversation in the Biotechnology practice conversations library before it happens for real. When you have this one down, read Assess a New Research Center Before Copying a Pilot Setup next.